Media and Communications


2006 News Releases

Monday, December 18, 2006
Teva Announces Launch Of Generic Wellbutrin Xl® Tablets, 300 Mg Under Agreement With Anchen And IMPAX

Jerusalem, Israel, December 18, 2006 - Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) announced today that it has commercially shipped Bupropion Hydrochloride Extended-Release Tablets, 300 mg, the generic version of Biovail Corporation's antidepressant Wellbutrin XL® Tablets, pursuant to an agreement with IMPAX Laboratories, Inc. (NASDAQ:IPXL) and Anchen Pharmaceuticals, Inc. Wellbutrin XL® Tablets, 300 mg, marketed by GlaxoSmithKline, had U.S. sales of approximately $972 million for the 12 months ended September 2006, according to IMS data.Under the agreement, Anchen has taken the regulat Read More »

Wednesday, November 29, 2006
Teva Announces Tentative Approval Of Sumatriptan Succinate Tablets

Jerusalem, Israel, November 29, 2006 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U.S. Food and Drug Administration has granted tentative approval for the Company's Abbreviated New Drug Application (ANDA) for Sumatriptan Succinate Tablets, 25 mg, 50 mg and 100 mg. Final approval is expected upon expiry of patent protection for the brand product in February 2009.Upon final approval, Teva's Sumatriptan Succinate Tablets will be the AB-rated generic equivalent of GlaxoSmithKline's Imitrex® Tablets, indicated for acute treatment of migraine headaches.The brand prod Read More »

Tuesday, November 21, 2006
Teva Announces Agreement With Pfizer Regarding Idarubicin, Azithromycin, And Epirubicin

Jerusalem, Israel, November 21, 2006 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that it has reached a comprehensive agreement with Pfizer Inc (NYSE: PFE) regarding idarubicin, azithromycin, and epirubicin and the sale of those generic products. The agreement resolves and dismisses all outstanding patent litigation filed by Pharmacia, a subsidiary of Pfizer against Sicor, a subsidiary of Teva, over Sicor's sales of generic idarubicin, an anti-cancer drug and all patent litigation brought by Pfizer over Teva's sale of generic azithromycin, an antibiotic. Furthermore, th Read More »

Tuesday, November 14, 2006
Court of Appeals Affirms Teva's Generic Zocor® Exclusivity

Jerusalem, Israel, November 14, 2006 - Teva Pharmaceutical Industries Ltd. (Nasdaq:TEVA) announced today that the U.S. Court of Appeals for the Federal Circuit affirmed at May 1, 2006 decision by the District Court awarding the Company 180-day exclusivity for its generic version of Merck's Zocor® (Simvastatin) Tablets.On June 23, 2006, Teva received final approval from the FDA to market its Simvastatin Tablets, 5 mg, 10 mg, 20 mg, and 40 mg and immediately commenced shipment of these products. As the first company to file an ANDA containing a paragraph IV certification for these strengths, Tev Read More »

Tuesday, November 07, 2006
Teva Reports Third Quarter 2006 Results

Jerusalem, Israel, November 7, 2006 - *Quarterly Net Sales of $2,286 Million, up 74% *Net Income of $606 Million, up 127%*Fully Diluted EPS of $0.74, up 85%*Cash flow from operations reached $793 millionJerusalem, Israel, November 7, 2006 Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) today reported results for the quarter ended September 30, 2006.Net Sales for the third quarter of 2006 increased 74% to $2,286 million, compared to $1,317 million in the third quarter of 2005. The main contributors to the year-over-year growth in sales were several new product launches in the U.S. and the in Read More »

Tuesday, November 07, 2006
Teva Announces $600 Million Securities Repurchase Program

Jerusalem, Israel, November 7, 2006 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that its Board of Directors has authorized the Company to repurchase, including through one or more subsidiaries, up to an aggregate of $600 million of its ordinary shares/ADRs and convertible debentures of its finance subsidiaries. The repurchase program, Teva's third such program in recent years, is designed to enhance shareholder value and to offset dilution due to share issuances under the Company's employee compensation plans.Given the Company's strong cash position and cash flow, the Read More »

Tuesday, October 31, 2006
Teva announces Global In-Market Third Quarter Sales of Copaxone® Increased 15% To $354 Million

Jerusalem, Israel,, October 31, 2006 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today, in conjunction with the release of the Sanofi-Aventis group's financial results, that global in-market sales of Copaxone® in the third quarter of 2006 grew by 15% as compared to the third quarter of 2005 and reached a record of $354 million. According to IMS, in the U.S. Copaxone® continues to outpace the market growth strengthening its leadership position with TRx and NRx shares increasing to 34% and 35.2%, respectively, as of September 2006. U.S. sales in the third quarter of 2006 incre Read More »

Thursday, October 26, 2006
Teva to Report Third Quarter 2006 Financial Results on

CONFERENCE CALL SCHEDULED FOR 8:45 AM ET Jerusalem, Israel, October 26, 2006 - Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) announced today that it will release its third quarter 2006 financial results on Tuesday, November 7, 2006, early in the morning (ET). The earnings release will be available on Teva's web site at will host a conference call and live webcast on that same day, at 08:45AM ET to discuss its third quarter 2006 results and overall business environment. A Question & Answer session will follow this discussion. Investors and other interested parti Read More »

Wednesday, October 18, 2006
Teva Announces Planned Retirement of President & CEO in 2007

Shlomo Yanai to Succeed as President & CEO Jerusalem, Israel, October 18, 2006 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that Israel Makov, 67, has announced his plans to retire as President and CEO during the course of 2007. Shlomo Yanai, 55, will join the company as President and CEO Designate during the first part of 2007. Mr. Makov will continue to work with Teva as a senior strategic advisor to the company for the next two years and, during the transition period, Messrs. Makov and Yanai, along with the board, will work together to ensure a seamless leadersh Read More »

Monday, October 16, 2006
Teva Announces Oxycontin® Litigation Dismissed; Settlement With Purdue Finalized

Jerusalem, Israel, October 16, 2006 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that patent infringement litigation pertaining to Teva's generic version of Purdue's OxyContin® (oxycodone HCl extended-release) Tablets has been dismissed by the United States District Court for the Southern District of New York pursuant to a settlement between Teva and The Purdue Frederick Company and certain of its affiliates. The full terms of the settlement will become effective today and are consistent with the terms previously disclosed by the parties on August 29, 2006. The settleme Read More »